CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxA heavyweight telehealth brand with brand-name access and a polished experience — but opaque compounded pricing.
Visit RoCoreAge Rx takes it with a higher Verdict Score — 94/100 to 87/100 (grade A vs B+). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Ro still earns its place — patients who want a big, brand-name-capable platform and insurance navigation.
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
| Metric | CoreAge Rx | Ro |
|---|---|---|
| Verdict Score | 94/100 | 87/100 |
| Grade | A | B+ |
| Semaglutide | $149/mo | Not disclosed |
| Tirzepatide | $349/mo | Not disclosed |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | No | Yes |
What we like
The caveats
What we like
The caveats
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Patients who want a big, brand-name-capable platform and insurance navigation.
Visit Ro Read the full Ro review →Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Ro does the reverse.
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.